Fosun Pharmaceutical

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

Retrieved on: 
Wednesday, December 16, 2020

On the premise of ensuring the safety and effectiveness of the vaccine, we actively support the marketing of the vaccine in China.

Key Points: 
  • On the premise of ensuring the safety and effectiveness of the vaccine, we actively support the marketing of the vaccine in China.
  • The BNT162b2 mRNA vaccine is a successful model of international R&D collaboration, Wu Yifang, Chairman and CEO of Fosun Pharma said.
  • We are pleased to reach the supply agreement with BioNTech, which is an important step in Fosun Pharma and BioNTech's efforts to achieve vaccine accessibility and affordability in China.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.

Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

Retrieved on: 
Thursday, September 17, 2020

Today Mr. Alon Bloomenfeld announced that Raziel Therapeutics has entered into a license agreement with Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).

Key Points: 
  • Today Mr. Alon Bloomenfeld announced that Raziel Therapeutics has entered into a license agreement with Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).
  • "Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets.
  • We see Fosun Pharma as an ideal partner to commercialize RZL-012 in the fast-growing aesthetic Chinese market, said Alon Bloomenfeld, president and chief executive officer at Raziel Therapeutics.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.

BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162

Retrieved on: 
Tuesday, September 15, 2020

BioNTech will use the milestone-based BMBF funding to support its contribution to the Companys mRNA vaccine program BNT162 that is being co-developed with its partners Pfizer Inc. and Fosun Pharma respectively.

Key Points: 
  • BioNTech will use the milestone-based BMBF funding to support its contribution to the Companys mRNA vaccine program BNT162 that is being co-developed with its partners Pfizer Inc. and Fosun Pharma respectively.
  • We are grateful for the significant support from the BMBF, which is helping us to provide a safe and effective vaccine as soon as possible following regulatory approval.
  • The funding is an important contribution to accelerate the development and scaling-up of our COVID-19 vaccine manufacturing capacities in Germany.
  • Most recently, BioNTech received approval from the German regulatory authority, the Paul-Ehrlich-Institut, to initiate the German arm of the global Phase 2/3 trial.

BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China

Retrieved on: 
Wednesday, August 5, 2020

BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.

Key Points: 
  • BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.
  • During the clinical development stage, BioNTech will provide the clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
  • If the vaccine receives marketing authorization in China, Fosun Pharma will exclusively commercialize the vaccine in Mainland China, Hong Kong and Macau Special Administration Regions and in Taiwan.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.

Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China

Retrieved on: 
Tuesday, July 28, 2020

Mr. Suen brings to Sensus nearly 20 years of business development, sales and regulatory experience supporting the distribution of U.S. medical devices and other products throughout Asia and in particular China.

Key Points: 
  • Mr. Suen brings to Sensus nearly 20 years of business development, sales and regulatory experience supporting the distribution of U.S. medical devices and other products throughout Asia and in particular China.
  • From 2010 to 2016 he was Senior Manager, Business Development and Regulatory at Chindex International, prior to its acquisition by Fosun Pharma.
  • We worked with Benson when he was with our China distributor, and know his abilities first-hand.
  • Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.

Fosun Pharma Invites Chinese and Foreign Experts to Jointly Discuss Prevention and Control Measures of COVID-19 Epidemic in Africa

Retrieved on: 
Wednesday, April 29, 2020

Since the COVID-19 outbreak, Fosun Pharma, an international pharmaceutical company, has taken an active part in the battle.

Key Points: 
  • Since the COVID-19 outbreak, Fosun Pharma, an international pharmaceutical company, has taken an active part in the battle.
  • Mr. Wu Yifang, President and CEO of Fosun Pharma, said, "Fosun Pharma has been operating in Africa for over decade and has nearly 1,000 employees there.
  • We are striving to control the spread of the epidemic by strengthening various case management measures."
  • Fosun Pharma hopes that these materials will help alleviate the burden on local health systems, facilitating the countries to reach their malaria prevention and control targets.

Fosun Pharma Receives FDA Emergency Use Authorization (EUA) For Its COVID-19 RT-PCR Detection Kit

Retrieved on: 
Sunday, April 19, 2020

SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration ("FDA"), Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) has received emergency use authorization (EUA) from FDA for itsCOVID-19 RT-PCR detection kit.

Key Points: 
  • SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration ("FDA"), Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) has received emergency use authorization (EUA) from FDA for itsCOVID-19 RT-PCR detection kit.
  • The testing kit which was self-developed by Fosun Long March, a wholly-owned subsidiary of Fosun Pharma, has received the medical device registration certificate issued by the China National Medical Products Administration (NMPA) and granted CE certification from the European Union ("EU").
  • Fosun Pharma has been engaged in the business of PCR hepatitis B virus diagnostic reagents since its establishment in 1994.
  • According to the company's FY2019 earnings results, the revenue of Fosun Pharma increased by 14.72% to RMB28,585million as compared to 2018.

From China to the World, Fosun's Fight against COVID-19 Continues

Retrieved on: 
Tuesday, April 7, 2020

Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.

Key Points: 
  • Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.
  • Chen Qiyu, Co-CEO of Fosun International and Chairman of Fosun Pharma, expressed his gratitude to the experts from all over the world.
  • Chen said: "Since January 23, Fosun's Wuhan Jihe Hospital is listed as a COVID-19 designated treatment hospital.
  • We have invested in the fight against the epidemic in all aspects.

From China to the World, Fosun's Fight against COVID-19 Continues

Retrieved on: 
Tuesday, April 7, 2020

Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.

Key Points: 
  • Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.
  • Chen Qiyu, Co-CEO of Fosun International and Chairman of Fosun Pharma, expressed his gratitude to the experts from all over the world.
  • Chen said: "Since January 23, Fosun's Wuhan Jihe Hospital is listed as a COVID-19 designated treatment hospital.
  • We have invested in the fight against the epidemic in all aspects.

BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

Retrieved on: 
Monday, March 16, 2020

As part of its global development program, BioNTech announced today a strategic alliance with Fosun Pharma to jointly develop its COVID-19 vaccine in China.

Key Points: 
  • As part of its global development program, BioNTech announced today a strategic alliance with Fosun Pharma to jointly develop its COVID-19 vaccine in China.
  • In addition, BioNTech is in advanced discussions with its existing collaborator Pfizer regarding the development of the vaccine outside China.
  • We feel a duty to exploit our full technology and immunotherapy expertise to help address the COVID-19 pandemic emergency.
  • BNT162 is BioNTechs mRNA vaccine program aimed at preventing COVID-19 infection and is the first product candidate from Project Lightspeed.